Porth's Essentials of Pathophysiology, 4e - page 279

260 U N I T 3 Hematopoietic Function
28. American Cancer Society. Acute myeloid leukemia. 2013.
Available at: http://www.cancer.org/acs/groups/cid/documents/
webcontent/003110-pdf.pdf. Accessed September 21, 2013.
29. Krug U, Búchner T, Burdel WE, et al. The treatment of elderly
patients with acute myeloid leukemia. Dtsch Arziebi Int.
2011;108(51–52):863–870.
30. American Cancer Society. Chronic lymphocytic leukemia. 2013.
Available at: http://www.cancer.org/acs/groups/cid/documents/
webcontent/003111-pdf.pdf. Accessed September 21, 2013.
31. Chiorazzi N, Rai KR, Farrarini M. Chronic lymphocytic
leukemia. N Engl J Med. 2005;352:804–815.
32. Malayssi F, Deaglio S, Damie G. CD38 and chronic lymphocytic
leukemia: a decade later. Blood. 2011;119(3):2470–3478.
33. American Cancer Society. Chronic myeloid leukemia. 2012.
Available at: http://www.cancer.org/acs/groups/cid/documents/
webcontent/003112-pdf.pdf. Accessed September 21, 2013.
34. Chen Y, Peng C, Sullivan C, et al. Critical molecular pathways
in cancer stem cells of chronic myeloid leukemia. Leukemia.
2010;24(9):1545–1554.
35. Cervantes F, Mauro M. Practical management of chronic myeloid
leukemia. Cancer. 2011;117:4343–4354.
36. Marin D. Initial choice of therapy among plenty for newly
diagnosed chronic myeloid leukemia. Hematology. 2012:115–121.
37. Mahon F-X. Is going for a cure in chronic myeloid leukemia
possible and justified. Hematology. 2012:122–128.
38. Goldman JM, Melo JV. Chronic myeloid leukemia: advances
in biology and new approaches to treatment. N Engl J Med.
2003;349:1451–1464.
39. Rademaker J. Hodgkin’s and non-Hodgkin’s lymphoma. Radiol
Clin North Am. 2007;45:69–83.
40. American Cancer Society. Non-Hodgkin lymphoma. 2013.
Available at: http://www.cancer.org/acs/groups/cid/documents/
webcontent/003126-pdf.pdf. Accessed September 21, 2013.
41. Armitage JO. Staging of non-Hodgkin lymphoma. CA Cancer J
Clin. 2005;55:368–376.
42. Lenz C, Staudt LM. Aggressive lymphomas. N Engl J Med.
2010;362(15):1417–1429.
43. Reiser M, Diehl V. Current treatment of follicular non-Hodgkin’s
lymphoma. Eur J Cancer. 2002;38:1167–1172.
44. American Cancer Society. Hodgkin disease. 2012. Available
at: http://www.cancer.org/acs/groups/cid/documents/
webcontent/003105-pdf.pdf. Accessed September 21, 2013.
45. Yung L, Linch D. Hodgkin’s lymphoma. Lancet
2003;361:943–951.
46. Conners JM. Hodgkin's lymphoma—the great teacher. N Engl J
Med. 2011;365(3):264–265.
47. Armitage JO. Early-stage Hodgkin’s lymphoma. N Engl J Med.
2010;363(7):653–662.
48. American Cancer Society. Multiple myeloma. 2013. Available
at: http://www.cancer.org/acs/groups/cid/documents/
webcontent/003126-pdf.pdf. Accessed September 21, 2013.
49. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med.
2011;364(11):1046–1060.
50. Raab MS, Podar K, Breitkreutz I, et al. Multiple myeloma.
Lancet. 2009;374:324–339.
51. Nau KC, Lewis WD. Multiple myeloma: diagnosis and
treatment. Am Fam Physician. 2008;78(7):853–860.
52. Katzel JA. Multiple myeloma: charging toward a bright future.
CA Cancer J Clin. 2007;57:301–318.
Porth Essentials Resources
Explore these additional resources to enhance learning
for this chapter:
• NCLEX-Style Questions and Other Resources
on ,http://thePoint.lww.com/PorthEssentials4e
• Study Guide for Essentials of Pathophysiology
• Adaptive Learning | Powered by PrepU,http://thepoint.lww.com/
prepu